Mirati Therapeutics, Inc. (NASDAQ:MRTX) issued its quarterly earnings results on Wednesday. The biotechnology company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.16, Bloomberg Earnings reports.

Mirati Therapeutics (MRTX) traded up $1.35 during trading on Friday, hitting $14.05. The company had a trading volume of 345,076 shares, compared to its average volume of 428,133.

A number of equities research analysts have recently weighed in on MRTX shares. ValuEngine upgraded Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 15th. Leerink Swann boosted their price target on Mirati Therapeutics from $7.00 to $9.00 and gave the stock a “market perform” rating in a research note on Friday, September 15th. Oppenheimer Holdings, Inc. started coverage on Mirati Therapeutics in a research note on Monday, September 18th. They set an “outperform” rating and a $18.00 price target on the stock. CIBC started coverage on Mirati Therapeutics in a research note on Tuesday, September 19th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Mirati Therapeutics in a research note on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Mirati Therapeutics has a consensus rating of “Hold” and an average target price of $13.88.

WARNING: “Mirati Therapeutics, Inc. (MRTX) Releases Earnings Results, Beats Expectations By $0.16 EPS” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/11/03/mirati-therapeutics-inc-mrtx-releases-earnings-results-beats-expectations-by-0-16-eps.html.

In related news, SVP Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $14.00, for a total transaction of $104,986.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold 12,269 shares of company stock valued at $170,226 in the last ninety days. Corporate insiders own 5.10% of the company’s stock.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Earnings History for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.